SG11201807652SA - Derivatives of amanita toxins and their conjugation to a cell binding molecule - Google Patents

Derivatives of amanita toxins and their conjugation to a cell binding molecule

Info

Publication number
SG11201807652SA
SG11201807652SA SG11201807652SA SG11201807652SA SG11201807652SA SG 11201807652S A SG11201807652S A SG 11201807652SA SG 11201807652S A SG11201807652S A SG 11201807652SA SG 11201807652S A SG11201807652S A SG 11201807652SA SG 11201807652S A SG11201807652S A SG 11201807652SA
Authority
SG
Singapore
Prior art keywords
hangzhou
heda
zhejiang
street
room
Prior art date
Application number
SG11201807652SA
Other languages
English (en)
Inventor
Robert Yongxin Zhao
Qingliang Yang
Yuanyuan Huang
Shun Gai
Hangbo Ye
Chengyu Yang
Huihui Guo
Xiaomai Zhou
Hongsheng Xie
Qianqian Tong
Minjun Cao
Linyao Zhao
Junxiang Jia
Wenjun Li
Xiaotao Zuo
Chen Lin
Yifang Xu
Zixiang Guo
Original Assignee
Hangzhou Dac Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Dac Biotech Co Ltd filed Critical Hangzhou Dac Biotech Co Ltd
Publication of SG11201807652SA publication Critical patent/SG11201807652SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201807652SA 2016-04-20 2016-04-20 Derivatives of amanita toxins and their conjugation to a cell binding molecule SG11201807652SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2016/052246 WO2017046658A1 (en) 2016-04-20 2016-04-20 Derivatives of amanita toxins and their conjugation to a cell binding molecule

Publications (1)

Publication Number Publication Date
SG11201807652SA true SG11201807652SA (en) 2018-10-30

Family

ID=58288166

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807652SA SG11201807652SA (en) 2016-04-20 2016-04-20 Derivatives of amanita toxins and their conjugation to a cell binding molecule

Country Status (15)

Country Link
US (1) US10836796B2 (es)
EP (1) EP3445401A4 (es)
JP (2) JP7295640B2 (es)
KR (1) KR102295190B1 (es)
CN (2) CN109689107B (es)
AU (1) AU2016322708B2 (es)
BR (1) BR112018071465A2 (es)
CA (1) CA3016172C (es)
MX (1) MX2018012803A (es)
MY (1) MY197235A (es)
NZ (1) NZ744936A (es)
PH (1) PH12018501777A1 (es)
SG (1) SG11201807652SA (es)
WO (1) WO2017046658A1 (es)
ZA (1) ZA201807613B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016059622A2 (en) 2016-02-04 2016-04-21 Suzhou M-Conj Biotech Co., Ltd. Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
MY197235A (en) * 2016-04-20 2023-06-07 Hangzhou Dac Biotech Co Ltd Derivatives of amanita toxins and their conjugation to a cell binding molecule
US20190328901A1 (en) 2016-06-17 2019-10-31 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cells
US20210308277A1 (en) * 2016-11-14 2021-10-07 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers
WO2018134787A2 (en) 2017-01-20 2018-07-26 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd137+ cells
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
BR112019020049A2 (pt) * 2017-04-06 2020-05-12 Hangzhou Dac Biotech Co., Ltd Composto conjungado, célula tumoral, composição farmacêutica, e, agentes sinérgicos.
JP7220199B2 (ja) * 2017-08-07 2023-02-09 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング アマニチンの新規な合成方法
CN114191564A (zh) * 2017-08-18 2022-03-18 四川百利药业有限责任公司 一种非天然鹅膏毒肽类抗体偶联物
KR20190043031A (ko) * 2017-10-17 2019-04-25 한국화학연구원 아마톡신 유도체 및 이의 제조방법
EP3700540A4 (en) * 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS OF DEPRODUCTION FROM CD117 + CELLS
MX2020004140A (es) 2017-10-24 2020-08-13 Magenta Therapeutics Inc Composiciones y metodos para la eliminacion de celulas cd117+.
KR102641565B1 (ko) * 2017-12-31 2024-02-27 항저우 디에이씨 바이오테크 씨오, 엘티디 분지형 링커를 갖는 튜불리신 유사체의 접합체
CN109096128B (zh) * 2018-01-12 2021-03-09 江苏金斯瑞生物科技有限公司 一种氨基聚乙二醇丙酸的制备方法
KR20210083282A (ko) * 2018-12-17 2021-07-06 레메젠 코, 리미티드 항체-약물 컨쥬게이트에 사용하기 위한 커넥터 및 커넥터의 적용
JP2022523103A (ja) * 2019-01-31 2022-04-21 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. 分岐連結体とアマニタトキシンとの共役体
EP3958908A1 (en) 2019-04-24 2022-03-02 Heidelberg Pharma Research GmbH Amatoxin antibody-drug conjugates and uses thereof
CN114040779A (zh) * 2019-06-24 2022-02-11 杭州多禧生物科技有限公司 含支链连接子的细胞结合分子与细胞毒性剂的偶联物
KR102092817B1 (ko) * 2019-08-22 2020-03-24 한국화학연구원 아마톡신 유도체 및 이의 제조방법
TWI710488B (zh) 2019-09-18 2020-11-21 亞慶股份有限公司 高爾夫球車煞車系統的自駕煞車暨手駕煞車連接組件
AR120218A1 (es) * 2019-10-15 2022-02-02 Heidelberg Pharma Res Gmbh Conjugados de amatoxina y anticuerpo específico de linfocitos b
US20230039142A1 (en) * 2019-12-16 2023-02-09 Heidelberg Pharma Research Gmbh Synthesis of amanin and its derivatives
CN111233949A (zh) * 2020-02-10 2020-06-05 天津科技大学 一种神经节苷脂gm3和/或其类似物、合成方法和应用
WO2021255217A1 (en) * 2020-06-19 2021-12-23 Heidelberg Pharma Research Gmbh Amatoxin and amatoxin conjugates for use in inhibition of rna virus replication
WO2024154763A1 (ja) * 2023-01-17 2024-07-25 大塚製薬株式会社 抗体薬物複合体用リンカーおよび抗体薬物複合体
CN116284224B (zh) * 2023-05-12 2023-07-25 中国农业大学 一种结合Claudin 18.2的环肽及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001270863A (ja) * 2000-03-23 2001-10-02 Mitsui Chemicals Inc 6−置換インドール誘導体の製造方法
CA2970774C (en) 2009-04-08 2019-01-08 Deutsches Krebsforschungszentrum Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
EP2436398B1 (en) * 2010-09-30 2013-01-23 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkers
DK2675479T3 (en) * 2011-02-15 2016-04-11 Immunogen Inc cytotoxic benzodiazepine
EP2497499A1 (en) 2011-03-10 2012-09-12 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkages
US20150218220A1 (en) 2012-09-12 2015-08-06 Brian Alan MENDELSOHN Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
WO2015028850A1 (en) * 2013-09-02 2015-03-05 Hangzhou Dac Biotech Co., Ltd Novel cytotoxic agents for conjugation of drugs to cell binding molecule
AU2015242213A1 (en) * 2015-07-12 2018-03-08 Hangzhou Dac Biotech Co., Ltd Bridge linkers for conjugation of cell-binding molecules
CA2991975C (en) * 2015-08-10 2021-04-06 Suzhou M-Conj Biotech Co., Ltd. Novel linkers and their uses in specific conjugation of drugs to a biological molecule
WO2016059622A2 (en) 2016-02-04 2016-04-21 Suzhou M-Conj Biotech Co., Ltd. Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
MY197235A (en) * 2016-04-20 2023-06-07 Hangzhou Dac Biotech Co Ltd Derivatives of amanita toxins and their conjugation to a cell binding molecule

Also Published As

Publication number Publication date
BR112018071465A2 (pt) 2019-02-05
CN109689107B (zh) 2022-08-16
EP3445401A4 (en) 2019-11-20
CA3016172C (en) 2024-03-12
KR20180125154A (ko) 2018-11-22
CN109689107A (zh) 2019-04-26
US10836796B2 (en) 2020-11-17
CN115181164A (zh) 2022-10-14
JP2019515907A (ja) 2019-06-13
MY197235A (en) 2023-06-07
US20200079820A1 (en) 2020-03-12
KR102295190B1 (ko) 2021-08-30
JP7295640B2 (ja) 2023-06-21
WO2017046658A1 (en) 2017-03-23
MX2018012803A (es) 2019-06-24
NZ744936A (en) 2022-01-28
AU2016322708A1 (en) 2018-08-23
AU2016322708B2 (en) 2020-08-20
PH12018501777A1 (en) 2019-05-15
CA3016172A1 (en) 2017-03-23
EP3445401A1 (en) 2019-02-27
JP2023051977A (ja) 2023-04-11
ZA201807613B (en) 2022-02-23

Similar Documents

Publication Publication Date Title
SG11201807652SA (en) Derivatives of amanita toxins and their conjugation to a cell binding molecule
SG11201908721TA (en) Conjugation of a cytotoxic drug with bis-linkage
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201906763RA (en) Pyrrolo [1,2-b] pyridazine derivatives
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201901390TA (en) Tetracycline compounds and methods of treatment
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201804915RA (en) Methods for treating huntington's disease
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201810485SA (en) Substituted carbonucleoside derivatives useful as anticancer agents
SG11201903287PA (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201901457TA (en) 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
SG11201901374WA (en) Antibiotic compounds
SG11201906163TA (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
SG11201811209QA (en) Oral gastroretentive formulations and uses thereof
SG11201906222WA (en) Jak1 selective inhibitors
SG11201906417RA (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201805001UA (en) Method of treating influenza a
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201809534UA (en) Methods of treating autoimmune disease using allogeneic t cells
SG11201809561WA (en) 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment
SG11201908226XA (en) Rapamycin analog